Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
ABIRATERONE + Mechlorethamine
|
DCLCQJA
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
ABIRATERONE + Mechlorethamine
|
DCQ7VNL
|
ABIRATERONE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
ABIRATERONE + Mechlorethamine
|
DC809J1
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
ABIRATERONE + Mechlorethamine
|
DC8LYYX
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Amonafide + Mechlorethamine
|
DCFUMKZ
|
Amonafide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Amonafide + Mechlorethamine
|
DCCZ5OK
|
Amonafide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
Amonafide + Mechlorethamine
|
DCEQGUW
|
Amonafide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Anastrozole + Mechlorethamine
|
DCMJQUH
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Anastrozole + Mechlorethamine
|
DCD4O0P
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
Anastrozole + Mechlorethamine
|
DCFGI3X
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
Anastrozole + Mechlorethamine
|
DCK36M3
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
Anastrozole + Mechlorethamine
|
DCR2GLB
|
Anastrozole
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
Anastrozole + Mechlorethamine
|
DCHRSX5
|
Anastrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
Anastrozole + Mechlorethamine
|
DCVI2G8
|
Anastrozole
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Anastrozole + Mechlorethamine
|
DCYXHU9
|
Anastrozole
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
BIO-300 + Mechlorethamine
|
DCGE830
|
BIO-300
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
BIO-300 + Mechlorethamine
|
DCXUHPA
|
BIO-300
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
Bleomycin + Mechlorethamine
|
DCGDQWF
|
Bleomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Bleomycin + Mechlorethamine
|
DCHXEAM
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Bleomycin + Mechlorethamine
|
DCE3E1F
|
Bleomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Bleomycin + Mechlorethamine
|
DCWATN3
|
Bleomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Bleomycin + Mechlorethamine
|
DCEFFNL
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Bleomycin + Mechlorethamine
|
DC8G39I
|
Bleomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[5] |
Bleomycin + Mechlorethamine
|
DCINSSA
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Bleomycin + Mechlorethamine
|
DCF7I2C
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Bleomycin + Mechlorethamine
|
DC788O2
|
Bleomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Bleomycin + Mechlorethamine
|
DCO5CGN
|
Bleomycin
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Bleomycin + Mechlorethamine
|
DC5K7A8
|
Bleomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Bleomycin + Mechlorethamine
|
DC6XOP7
|
Bleomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Cabazitaxel + Mechlorethamine
|
DCT13C4
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
Cabazitaxel + Mechlorethamine
|
DC0CI34
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
Cabazitaxel + Mechlorethamine
|
DCMJCEP
|
Cabazitaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Cabazitaxel + Mechlorethamine
|
DCTGFVJ
|
Cabazitaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Cabazitaxel + Mechlorethamine
|
DC4W2HW
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
Cabazitaxel + Mechlorethamine
|
DC8RETM
|
Cabazitaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
Cabazitaxel + Mechlorethamine
|
DCIGWFK
|
Cabazitaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
Crizotinib + Mechlorethamine
|
DCV0G8A
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Crizotinib + Mechlorethamine
|
DCDI92C
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Crizotinib + Mechlorethamine
|
DCFZYZA
|
Crizotinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
Crizotinib + Mechlorethamine
|
DCGUPUO
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Dacarbazine + Mechlorethamine
|
DCGI0SS
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Dacarbazine + Mechlorethamine
|
DCO2557
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
Dexrazoxane + Mechlorethamine
|
DC6DF7D
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Dexrazoxane + Mechlorethamine
|
DCWG9CN
|
Dexrazoxane
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
Dexrazoxane + Mechlorethamine
|
DCF6K8B
|
Dexrazoxane
|
Glioma (Cell Line: SF-268)
|
[4] |
Dexrazoxane + Mechlorethamine
|
DC5A2ZB
|
Dexrazoxane
|
Glioma (Cell Line: SF-539)
|
[4] |
Dexrazoxane + Mechlorethamine
|
DCQI14E
|
Dexrazoxane
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Dexrazoxane + Mechlorethamine
|
DCTE1X3
|
Dexrazoxane
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Dexrazoxane + Mechlorethamine
|
DCTYD32
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
Dexrazoxane + Mechlorethamine
|
DCPC4UF
|
Dexrazoxane
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Dexrazoxane + Mechlorethamine
|
DCHWF7E
|
Dexrazoxane
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
Dexrazoxane + Mechlorethamine
|
DCF2FWX
|
Dexrazoxane
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Epirubicin + Mechlorethamine
|
DC6CN26
|
Epirubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Epirubicin + Mechlorethamine
|
DC9LSPA
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
Epirubicin + Mechlorethamine
|
DC04J7X
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Epirubicin + Mechlorethamine
|
DCCP669
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Epirubicin + Mechlorethamine
|
DCSRTVC
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Epirubicin + Mechlorethamine
|
DCVQA2X
|
Epirubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Epirubicin + Mechlorethamine
|
DC33YRT
|
Epirubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Gefitinib + Mechlorethamine
|
DCLY3VE
|
Gefitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Gefitinib + Mechlorethamine
|
DCON7X0
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Gefitinib + Mechlorethamine
|
DCZR3YA
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
Gefitinib + Mechlorethamine
|
DCXKX59
|
Gefitinib
|
Glioma (Cell Line: SF-539)
|
[4] |
Gefitinib + Mechlorethamine
|
DCZ09GC
|
Gefitinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
Gefitinib + Mechlorethamine
|
DCIT7PM
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
Gefitinib + Mechlorethamine
|
DCWUL9P
|
Gefitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Gefitinib + Mechlorethamine
|
DCTNAE6
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Indazole derivative 5 + Mechlorethamine
|
DC3GRIW
|
Indazole derivative 5
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Indazole derivative 5 + Mechlorethamine
|
DCMR0AI
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Indazole derivative 5 + Mechlorethamine
|
DCDEHKX
|
Indazole derivative 5
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Indazole derivative 5 + Mechlorethamine
|
DCBZQM5
|
Indazole derivative 5
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Lenalidomide + Mechlorethamine
|
DCG6O7K
|
Lenalidomide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Lenalidomide + Mechlorethamine
|
DC948XM
|
Lenalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Lenalidomide + Mechlorethamine
|
DCIV1GZ
|
Lenalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Lenalidomide + Mechlorethamine
|
DC1MYHO
|
Lenalidomide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Pentostatin
|
DCZNS00
|
Pentostatin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Picoplatin
|
DCYCJI7
|
Picoplatin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Picoplatin
|
DCAG2ZB
|
Picoplatin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
Mechlorethamine + Picoplatin
|
DCCTUUE
|
Picoplatin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + Picoplatin
|
DCMM7V0
|
Picoplatin
|
Glioma (Cell Line: SF-268)
|
[4] |
Mechlorethamine + Fulvestrant
|
DCIL5UE
|
Fulvestrant
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Hepzato
|
DCJENEJ
|
Hepzato
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
Mechlorethamine + Ixabepilone
|
DC50GUQ
|
Ixabepilone
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Dactinomycin
|
DC1ZO3V
|
Dactinomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Dactinomycin
|
DCM30V3
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Dactinomycin
|
DC6YS82
|
Dactinomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Mechlorethamine + Dactinomycin
|
DC10ZTP
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
Mechlorethamine + Dactinomycin
|
DCDM3YB
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Dactinomycin
|
DCQEB4V
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[4] |
Mechlorethamine + Dactinomycin
|
DCWGE68
|
Dactinomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Mechlorethamine + Dactinomycin
|
DCAZ2N1
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + DFN-15
|
DCQRZMV
|
DFN-15
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Lapatinib
|
DCFOTU7
|
Lapatinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Crizotinib
|
DC6EF8A
|
Crizotinib
|
Glioma (Cell Line: SF-295)
|
[4] |
Mechlorethamine + Crizotinib
|
DCREBIA
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Cyclophosphamide
|
DC4TSJM
|
Cyclophosphamide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Cyclophosphamide
|
DCCDJ0Z
|
Cyclophosphamide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + LIAROZOLE
|
DCJAH39
|
LIAROZOLE
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + LIAROZOLE
|
DCG78Y9
|
LIAROZOLE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Isoniazid
|
DC8ZEPY
|
Isoniazid
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Isoniazid
|
DCNL966
|
Isoniazid
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Isoniazid
|
DCO8HC7
|
Isoniazid
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
Mechlorethamine + Arsenic trioxide
|
DCOWU0S
|
Arsenic trioxide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Mechlorethamine + Arsenic trioxide
|
DCEIULB
|
Arsenic trioxide
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
Mechlorethamine + Arsenic trioxide
|
DCF4FRF
|
Arsenic trioxide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Vemurafenib
|
DCV5ZB4
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Vemurafenib
|
DCT3Z0O
|
Vemurafenib
|
Glioma (Cell Line: SF-295)
|
[4] |
Mechlorethamine + Vemurafenib
|
DC4H4OE
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Vemurafenib
|
DCWF584
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
Mechlorethamine + Plicamycin
|
DCRJ2VC
|
Plicamycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Plicamycin
|
DCMUMIE
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Plicamycin
|
DC616H4
|
Plicamycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Plicamycin
|
DCEMD40
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
Mechlorethamine + Plicamycin
|
DCL3K73
|
Plicamycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Plicamycin
|
DCRX4J5
|
Plicamycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
Mechlorethamine + Nilotinib
|
DCDMAD1
|
Nilotinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Nilotinib
|
DCIY505
|
Nilotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Thioguanine
|
DCEZL9R
|
Thioguanine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Thioguanine
|
DCRN3XI
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
Mechlorethamine + Triapine
|
DC7KHPQ
|
Triapine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Triapine
|
DC3B4H5
|
Triapine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Terameprocol
|
DCQVOA4
|
Terameprocol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Terameprocol
|
DCQXBSO
|
Terameprocol
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Terameprocol
|
DCDY0E5
|
Terameprocol
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Mechlorethamine + Terameprocol
|
DCF57TJ
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
Mechlorethamine + Terameprocol
|
DC7CKHE
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
Mechlorethamine + Terameprocol
|
DCAS6UE
|
Terameprocol
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
Mechlorethamine + Terameprocol
|
DCIXYTE
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + SCH 727965
|
DCQOJIT
|
SCH 727965
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + SCH 727965
|
DC4G4UG
|
SCH 727965
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Ifosfamide
|
DC7ORA7
|
Ifosfamide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Ifosfamide
|
DC3TE8X
|
Ifosfamide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Ifosfamide
|
DCIFBII
|
Ifosfamide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Mechlorethamine + Ifosfamide
|
DCDS1DV
|
Ifosfamide
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
Mechlorethamine + Ifosfamide
|
DC9XPRB
|
Ifosfamide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Ifosfamide
|
DC812A6
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
Mechlorethamine + Ifosfamide
|
DC7G7RL
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + Ifosfamide
|
DC5S3AR
|
Ifosfamide
|
Glioma (Cell Line: SF-268)
|
[4] |
Mechlorethamine + Ifosfamide
|
DCPIKPQ
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Ifosfamide
|
DCS6G7J
|
Ifosfamide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
Mechlorethamine + Raloxifene
|
DCWF65T
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
Mechlorethamine + Bendamustine hydrochloride
|
DCRO0KI
|
Bendamustine hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Letrozole
|
DCTRAXL
|
Letrozole
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Mitomycin
|
DCA2P3L
|
Mitomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Mechlorethamine + Mitomycin
|
DCH3XCH
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + Mitomycin
|
DCL6Y1W
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
Mechlorethamine + SY-1425
|
DCFXASA
|
SY-1425
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
Mechlorethamine + SY-1425
|
DCP1CG5
|
SY-1425
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + SY-1425
|
DCTI2GI
|
SY-1425
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
Mechlorethamine + Vincristine
|
DCEJEEI
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
Mechlorethamine + Altretamine
|
DC0XTF6
|
Altretamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Altretamine
|
DCHVHE5
|
Altretamine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
Mechlorethamine + Altretamine
|
DCRH7QH
|
Altretamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Altretamine
|
DCMZGU1
|
Altretamine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + Altretamine
|
DCY3HUV
|
Altretamine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Mechlorethamine + TEM
|
DCYPMT1
|
TEM
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + TEM
|
DCQ86L3
|
TEM
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
Mechlorethamine + Bleomycin
|
DCFSNFN
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Bleomycin
|
DC51QY3
|
Bleomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Bortezomib
|
DCBQ3R5
|
Bortezomib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Bortezomib
|
DCNU1X2
|
Bortezomib
|
Astrocytoma (Cell Line: U251)
|
[4] |
Mechlorethamine + Bortezomib
|
DC8KB9Q
|
Bortezomib
|
Glioma (Cell Line: SF-295)
|
[4] |
Mechlorethamine + Bortezomib
|
DC1IS24
|
Bortezomib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Mechlorethamine + Valrubicin
|
DCFOFM8
|
Valrubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Valrubicin
|
DCDS61R
|
Valrubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
Mechlorethamine + Valrubicin
|
DC40A28
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Topotecan
|
DC4V9VY
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
Mechlorethamine + Topotecan
|
DCMC452
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[4] |
Mechlorethamine + Topotecan
|
DCO57HY
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
Mechlorethamine + Chlorambucil
|
DC4ZT4B
|
Chlorambucil
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + ER819762
|
DCBOWUV
|
ER819762
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + ER819762
|
DCAMP0Y
|
ER819762
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Azacitidine
|
DC7F3JJ
|
Azacitidine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCFHBBU
|
Pomalidomide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Pomalidomide
|
DCMEMC7
|
Pomalidomide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCHRAF0
|
Pomalidomide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCOUD09
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCWFYJN
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCTLYTO
|
Pomalidomide
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCMELCS
|
Pomalidomide
|
Glioma (Cell Line: SF-295)
|
[4] |
Mechlorethamine + Pomalidomide
|
DC1NRWG
|
Pomalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Pomalidomide
|
DCR8PC8
|
Pomalidomide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
Mechlorethamine + Vinflunine
|
DC1XN3T
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Mepacrine
|
DC2GWLW
|
Mepacrine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + Mepacrine
|
DCKHI74
|
Mepacrine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
Mechlorethamine + Fludarabine
|
DC72ATW
|
Fludarabine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + PMID28870136-Compound-43
|
DCUK7K1
|
PMID28870136-Compound-43
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Mechlorethamine + FORMESTANE
|
DC284KS
|
FORMESTANE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Estramustine
|
DCWAON1
|
Estramustine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Mechlorethamine + Busulfan
|
DCMUQV7
|
Busulfan
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Dasatinib
|
DCI6ADI
|
Dasatinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Mechlorethamine + Dasatinib
|
DCWV2WW
|
Dasatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Mechlorethamine + Picoplatin
|
DC9OYR3
|
Picoplatin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[6] |
Mechlorethamine + Dactinomycin
|
DCGOIX9
|
Dactinomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[6] |
Mechlorethamine + Dactinomycin
|
DC76ZHD
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + Dactinomycin
|
DCWEMUW
|
Dactinomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Dactinomycin
|
DC7ZVPT
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + Dactinomycin
|
DCOLKZG
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[6] |
Mechlorethamine + PMID28460551-Compound-2
|
DCAXYS0
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + PMID28460551-Compound-2
|
DCXCBG0
|
PMID28460551-Compound-2
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + LIAROZOLE
|
DCNGPLA
|
LIAROZOLE
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + Methotrexate
|
DC4DP9D
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + Isoniazid
|
DC11IQ8
|
Isoniazid
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Arsenic trioxide
|
DCT8YA3
|
Arsenic trioxide
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Vemurafenib
|
DCFD93E
|
Vemurafenib
|
Carcinoma (Cell Line: MCF7)
|
[6] |
Mechlorethamine + Vemurafenib
|
DCCU4ZE
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[6] |
Mechlorethamine + Plicamycin
|
DC3SGI7
|
Plicamycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Plicamycin
|
DC1R2Z7
|
Plicamycin
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Plicamycin
|
DC751JV
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[6] |
Mechlorethamine + Nilotinib
|
DCONJZR
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + Thioguanine
|
DCX8AHY
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Thioguanine
|
DCT2JVH
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + Terameprocol
|
DC34PQ7
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Ifosfamide
|
DCZJOO4
|
Ifosfamide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[6] |
Mechlorethamine + Ifosfamide
|
DCFB62O
|
Ifosfamide
|
Carcinoma (Cell Line: MCF7)
|
[6] |
Mechlorethamine + Ifosfamide
|
DC3ZJRA
|
Ifosfamide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Ifosfamide
|
DCM8BP0
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + Ifosfamide
|
DCO4KI0
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[6] |
Mechlorethamine + Ifosfamide
|
DC1S2M8
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + Raloxifene
|
DC0S7RW
|
Raloxifene
|
Carcinoma (Cell Line: MCF7)
|
[6] |
Mechlorethamine + Raloxifene
|
DCVG2C6
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + Mitomycin
|
DCFOFEJ
|
Mitomycin
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + Mitomycin
|
DCGXOAF
|
Mitomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Mitomycin
|
DCAYDYU
|
Mitomycin
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Mitomycin
|
DCBSYKM
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + SY-1425
|
DCLN6UZ
|
SY-1425
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Arfolitixorin
|
DCBD9F9
|
Arfolitixorin
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + Arfolitixorin
|
DCCFOO5
|
Arfolitixorin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Arfolitixorin
|
DCK6CEH
|
Arfolitixorin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + Altretamine
|
DCEND2Y
|
Altretamine
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + Altretamine
|
DCHOB8Y
|
Altretamine
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Altretamine
|
DC8ZNBG
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + TEM
|
DCRSEXV
|
TEM
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + TEM
|
DCRHOZH
|
TEM
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[6] |
Mechlorethamine + Bortezomib
|
DCFGY0L
|
Bortezomib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Bortezomib
|
DCOX9W2
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + Valrubicin
|
DC6BDYI
|
Valrubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Valrubicin
|
DCCIUXH
|
Valrubicin
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Topotecan
|
DC2Q8TC
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + Cisplatin
|
DCNRX3R
|
Cisplatin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[6] |
Mechlorethamine + Cisplatin
|
DCI233K
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[6] |
Mechlorethamine + ER819762
|
DCZYUPP
|
ER819762
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[6] |
Mechlorethamine + Pomalidomide
|
DCTAJ57
|
Pomalidomide
|
Carcinoma (Cell Line: RXF 393)
|
[6] |
Mechlorethamine + Pomalidomide
|
DCCASKI
|
Pomalidomide
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Mercaptopurine
|
DCOPLJL
|
Mercaptopurine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Mechlorethamine + Mepacrine
|
DCLRTUV
|
Mepacrine
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Digitoxin
|
DCNKQ6P
|
Digitoxin
|
Colon carcinoma (Cell Line: KM12)
|
[6] |
Mechlorethamine + Digitoxin
|
DCNNYGC
|
Digitoxin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[6] |
Mechlorethamine + Dasatinib
|
DC6JLZH
|
Dasatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[6] |
Mechlorethamine + Dasatinib
|
DCKM10J
|
Dasatinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Mechlorethamine + Pentostatin
|
DCVGN33
|
Pentostatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Picoplatin
|
DC1LL3V
|
Picoplatin
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + Picoplatin
|
DC46DXK
|
Picoplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Picoplatin
|
DC4KX7M
|
Picoplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Picoplatin
|
DCC6MML
|
Picoplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Picoplatin
|
DC2BUNW
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + Picoplatin
|
DCQZ3UY
|
Picoplatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Picoplatin
|
DCGIBEJ
|
Picoplatin
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Mechlorethamine + Picoplatin
|
DC4GSHV
|
Picoplatin
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
Mechlorethamine + Hepzato
|
DC4SXP8
|
Hepzato
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Hepzato
|
DCOPGU4
|
Hepzato
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + Hepzato
|
DCZH20J
|
Hepzato
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Dactinomycin
|
DC2XZKR
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCYR82L
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCK9FB2
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCTA2O7
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCUOX2Z
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCZKOWT
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCQ6A3F
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCVI4VN
|
Dactinomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCXN3JB
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCUBZFC
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCO5I5Q
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCUVSSU
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCWPTDK
|
Dactinomycin
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
Mechlorethamine + Dactinomycin
|
DCUNV22
|
Dactinomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Mechlorethamine + Dactinomycin
|
DC1P9EM
|
Dactinomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
Mechlorethamine + DFN-15
|
DCCP1DU
|
DFN-15
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + DFN-15
|
DCIGY58
|
DFN-15
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Mechlorethamine + DFN-15
|
DC705YT
|
DFN-15
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
Mechlorethamine + DFN-15
|
DC0ACJE
|
DFN-15
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + DFN-15
|
DCH92KF
|
DFN-15
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
Mechlorethamine + Lapatinib
|
DCXEZS4
|
Lapatinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
Mechlorethamine + Lapatinib
|
DC29HB8
|
Lapatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Crizotinib
|
DC1GW5M
|
Crizotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
Mechlorethamine + Crizotinib
|
DC27ILS
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Mechlorethamine + Crizotinib
|
DC290MY
|
Crizotinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Crizotinib
|
DC9XG16
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Cyclophosphamide
|
DCWBMH9
|
Cyclophosphamide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + LIAROZOLE
|
DCUT1M5
|
LIAROZOLE
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Mechlorethamine + Methotrexate
|
DCW7RQY
|
Methotrexate
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
Mechlorethamine + Isoniazid
|
DCOD4LF
|
Isoniazid
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Isoniazid
|
DCXM42T
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Mechlorethamine + Isoniazid
|
DC0QV5A
|
Isoniazid
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Mechlorethamine + Arsenic trioxide
|
DCE7VNY
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Arsenic trioxide
|
DC9JANL
|
Arsenic trioxide
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
Mechlorethamine + Arsenic trioxide
|
DCN4O90
|
Arsenic trioxide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Arsenic trioxide
|
DCYCN5H
|
Arsenic trioxide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Arsenic trioxide
|
DC3WWTN
|
Arsenic trioxide
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + Arsenic trioxide
|
DCEEJFW
|
Arsenic trioxide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Vemurafenib
|
DCPMI2S
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Vemurafenib
|
DCSNA4K
|
Vemurafenib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + Vemurafenib
|
DCW3LT4
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Mechlorethamine + Vemurafenib
|
DCWXGMJ
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
Mechlorethamine + Vemurafenib
|
DCV4RGA
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Vemurafenib
|
DC1DGAI
|
Vemurafenib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Plicamycin
|
DC197KT
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Plicamycin
|
DCU8AR9
|
Plicamycin
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
Mechlorethamine + Plicamycin
|
DCFALYD
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Plicamycin
|
DCZVFBT
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Plicamycin
|
DCZ4V9A
|
Plicamycin
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + Plicamycin
|
DCRVZW1
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
Mechlorethamine + Plicamycin
|
DCOQUWW
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Nilotinib
|
DCEPWMM
|
Nilotinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Nilotinib
|
DCBI7G4
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Mechlorethamine + Nilotinib
|
DCBTEH5
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Thioguanine
|
DC30CKD
|
Thioguanine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
Mechlorethamine + Thioguanine
|
DCGJCCT
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Thioguanine
|
DC74JFW
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Thioguanine
|
DC2OVLQ
|
Thioguanine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Thioguanine
|
DCPX91S
|
Thioguanine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Thioguanine
|
DCXVPGH
|
Thioguanine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Mechlorethamine + Thioguanine
|
DCDXMT2
|
Thioguanine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Mechlorethamine + Thioguanine
|
DCZEDC2
|
Thioguanine
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
Mechlorethamine + Triapine
|
DCE2WAM
|
Triapine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + 10-hydroxycamptothecin
|
DCKHV4K
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Topetecan
|
DCHTC06
|
Topetecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Pralatrexate
|
DCI94RW
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Pralatrexate
|
DCBU5CK
|
Pralatrexate
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Terameprocol
|
DCVW9CP
|
Terameprocol
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + Terameprocol
|
DCH9SFP
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + Terameprocol
|
DCOK1FQ
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Terameprocol
|
DC00D2V
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Mechlorethamine + Terameprocol
|
DCJWEHK
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Mechlorethamine + Terameprocol
|
DCHK5V5
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Terameprocol
|
DCUTZLX
|
Terameprocol
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + SCH 727965
|
DCFZWV6
|
SCH 727965
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + SCH 727965
|
DC4J9T9
|
SCH 727965
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCOLGI2
|
Ifosfamide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
Mechlorethamine + Ifosfamide
|
DC9IPPM
|
Ifosfamide
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCD0SA6
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCGWPB6
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCYG3JI
|
Ifosfamide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCQG6VO
|
Ifosfamide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCAIJAZ
|
Ifosfamide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCO4N2X
|
Ifosfamide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCM3Y5V
|
Ifosfamide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
Mechlorethamine + Ifosfamide
|
DC3YUU8
|
Ifosfamide
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCFMO62
|
Ifosfamide
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCKCEYF
|
Ifosfamide
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Ifosfamide
|
DCQ57DE
|
Ifosfamide
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
Mechlorethamine + Docetaxel
|
DCPHRJA
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Docetaxel
|
DCRZLY1
|
Docetaxel
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
Mechlorethamine + Raloxifene
|
DCKE2FZ
|
Raloxifene
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + Raloxifene
|
DCFTCEO
|
Raloxifene
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + Raloxifene
|
DCXYBLK
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Raloxifene
|
DCZ34EO
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Mechlorethamine + Raloxifene
|
DCFQ97O
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
Mechlorethamine + Raloxifene
|
DCLEX8Y
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + Raloxifene
|
DC01XLF
|
Raloxifene
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Bendamustine hydrochloride
|
DC9SI9I
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + Bendamustine hydrochloride
|
DCCAZX6
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Mechlorethamine + Bendamustine hydrochloride
|
DCT31IM
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Bendamustine hydrochloride
|
DC7YWAM
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
Mechlorethamine + Bendamustine hydrochloride
|
DCOT6AK
|
Bendamustine hydrochloride
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Mechlorethamine + Letrozole
|
DCH7WLL
|
Letrozole
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Letrozole
|
DCT1ZPM
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Mitomycin
|
DCIRXY8
|
Mitomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Mitomycin
|
DCZ2EZN
|
Mitomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Mechlorethamine + Mitomycin
|
DCLI5S9
|
Mitomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + SY-1425
|
DC4LPQP
|
SY-1425
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + SY-1425
|
DC7YHX2
|
SY-1425
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + SY-1425
|
DCLGHCC
|
SY-1425
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + SY-1425
|
DCH343O
|
SY-1425
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + SY-1425
|
DCX8JCU
|
SY-1425
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + SY-1425
|
DCJ5RJM
|
SY-1425
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + SY-1425
|
DCYVPBH
|
SY-1425
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + SY-1425
|
DCT64U7
|
SY-1425
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Mechlorethamine + SY-1425
|
DC4FUXX
|
SY-1425
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
Mechlorethamine + SY-1425
|
DCBFSEB
|
SY-1425
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Arfolitixorin
|
DC7V0TO
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
Mechlorethamine + Arfolitixorin
|
DC6LLQI
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Arfolitixorin
|
DCTYLQI
|
Arfolitixorin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Arfolitixorin
|
DCCSD19
|
Arfolitixorin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Arfolitixorin
|
DCEEKGA
|
Arfolitixorin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Mechlorethamine + Altretamine
|
DCA8AH8
|
Altretamine
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + Altretamine
|
DC05GKH
|
Altretamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Altretamine
|
DCA06JB
|
Altretamine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Mechlorethamine + Altretamine
|
DCDIWH7
|
Altretamine
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + Altretamine
|
DCHWN51
|
Altretamine
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
Mechlorethamine + Altretamine
|
DCUOG4X
|
Altretamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Altretamine
|
DC1Q378
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Altretamine
|
DCJF02T
|
Altretamine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + Altretamine
|
DCNHI9W
|
Altretamine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
Mechlorethamine + Altretamine
|
DCLPG98
|
Altretamine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Altretamine
|
DCPDMOX
|
Altretamine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Altretamine
|
DCPX06S
|
Altretamine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Mechlorethamine + Altretamine
|
DC6M66B
|
Altretamine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + TEM
|
DC9M383
|
TEM
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
Mechlorethamine + TEM
|
DCU15WO
|
TEM
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + TEM
|
DC7YADA
|
TEM
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + TEM
|
DCWCAR0
|
TEM
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Mechlorethamine + TEM
|
DCL34AP
|
TEM
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + TEM
|
DCUURN3
|
TEM
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
Mechlorethamine + TEM
|
DC5E0U8
|
TEM
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
Mechlorethamine + TEM
|
DC553A3
|
TEM
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + TEM
|
DC6IIXX
|
TEM
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + TEM
|
DCTAFW1
|
TEM
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
Mechlorethamine + Idarubicin
|
DC74XL2
|
Idarubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Idarubicin
|
DC0GY1C
|
Idarubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Idarubicin
|
DC8PCAP
|
Idarubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Idarubicin
|
DCNNYGX
|
Idarubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Idarubicin
|
DCI1QTA
|
Idarubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Idarubicin
|
DCMCYZC
|
Idarubicin
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Mechlorethamine + Imatinib
|
DCDGI0O
|
Imatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
Mechlorethamine + Imatinib
|
DC0YVIF
|
Imatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Imatinib
|
DC8ILC5
|
Imatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Bleomycin
|
DC4COPS
|
Bleomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
Mechlorethamine + Bleomycin
|
DCISD7X
|
Bleomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Bortezomib
|
DCUFOCE
|
Bortezomib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Bortezomib
|
DC8UOMB
|
Bortezomib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
Mechlorethamine + Bortezomib
|
DCK7ZKL
|
Bortezomib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Bortezomib
|
DCVET3F
|
Bortezomib
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Mechlorethamine + Valrubicin
|
DCSRMLV
|
Valrubicin
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Mechlorethamine + Valrubicin
|
DC221SE
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Valrubicin
|
DCZ0XK3
|
Valrubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Valrubicin
|
DCO86ZO
|
Valrubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Valrubicin
|
DCM81MY
|
Valrubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
Mechlorethamine + Valrubicin
|
DCAMPV2
|
Valrubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
Mechlorethamine + Topotecan
|
DC7W0Y4
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Topotecan
|
DCU364D
|
Topotecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Topotecan
|
DCKI2X6
|
Topotecan
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Mechlorethamine + Topotecan
|
DCGL3SR
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
Mechlorethamine + Topotecan
|
DCDAX35
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Topotecan
|
DCR5YQQ
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
Mechlorethamine + Cisplatin
|
DCKQCO6
|
Cisplatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Cisplatin
|
DCF0E37
|
Cisplatin
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
Mechlorethamine + Cisplatin
|
DC91RCI
|
Cisplatin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Cisplatin
|
DCM77EL
|
Cisplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Cisplatin
|
DCSLBST
|
Cisplatin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
Mechlorethamine + Chlorambucil
|
DCPKUY2
|
Chlorambucil
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + Chlorambucil
|
DCVOLGN
|
Chlorambucil
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Chlorambucil
|
DC4PQ9E
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
Mechlorethamine + Chlorambucil
|
DCTLNJB
|
Chlorambucil
|
Melanoma (Cell Line: UACC-257)
|
[5] |
Mechlorethamine + ER819762
|
DCRZ6CK
|
ER819762
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
Mechlorethamine + ER819762
|
DCXZVAL
|
ER819762
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
Mechlorethamine + ER819762
|
DCVLYWG
|
ER819762
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + ER819762
|
DCTJK7Q
|
ER819762
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + ER819762
|
DCX1OE6
|
ER819762
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
Mechlorethamine + Romidepsin
|
DC2ZX8K
|
Romidepsin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Mechlorethamine + Romidepsin
|
DC0L1G0
|
Romidepsin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Mechlorethamine + Azacitidine
|
DCGTR1C
|
Azacitidine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Azacitidine
|
DCGVCLQ
|
Azacitidine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Azacitidine
|
DCVQDMG
|
Azacitidine
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + Pomalidomide
|
DCTEOC1
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Pomalidomide
|
DC94RWB
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Mechlorethamine + Pomalidomide
|
DCR9RM2
|
Pomalidomide
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
Mechlorethamine + Pomalidomide
|
DCZD9PK
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Pomalidomide
|
DC39MQT
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Mechlorethamine + Pomalidomide
|
DCKI64Q
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Mechlorethamine + Pomalidomide
|
DCASP9E
|
Pomalidomide
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + Pomalidomide
|
DCKSJA8
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
Mechlorethamine + Mepacrine
|
DCNSWNO
|
Mepacrine
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
Mechlorethamine + Mepacrine
|
DCH8RJD
|
Mepacrine
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Mechlorethamine + Mepacrine
|
DC34G8K
|
Mepacrine
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
Mechlorethamine + PMID28870136-Compound-43
|
DCWDEBR
|
PMID28870136-Compound-43
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Estramustine
|
DCKSJRC
|
Estramustine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
Mechlorethamine + Digitoxin
|
DCTZLPY
|
Digitoxin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Mechlorethamine + Busulfan
|
DCCH36P
|
Busulfan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
Mechlorethamine + Busulfan
|
DCHPNYE
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
Mechlorethamine + Dasatinib
|
DCSG695
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Raloxifene + Mechlorethamine
|
DC6IJ0N
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Raloxifene + Mechlorethamine
|
DCE8HTJ
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
Raloxifene + Mechlorethamine
|
DCZEW1H
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
Raloxifene + Mechlorethamine
|
DCD0FK6
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[6] |
Raloxifene + Mechlorethamine
|
DCFP32S
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
Raloxifene + Mechlorethamine
|
DCONXFB
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Ruxolitinib + Mechlorethamine
|
DCRCT2J
|
Ruxolitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Ruxolitinib + Mechlorethamine
|
DCDAAOJ
|
Ruxolitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
Ruxolitinib + Mechlorethamine
|
DC0M3D3
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
Ruxolitinib + Mechlorethamine
|
DC0EQCO
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Ruxolitinib + Mechlorethamine
|
DCIO8UI
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
Ruxolitinib + Mechlorethamine
|
DC4TFIK
|
Ruxolitinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Trifluridine + Mechlorethamine
|
DC4J5ED
|
Trifluridine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Trifluridine + Mechlorethamine
|
DC23Y6S
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[6] |
Trifluridine + Mechlorethamine
|
DCKMRID
|
Trifluridine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Uracil mustard + Mechlorethamine
|
DCFEL8F
|
Uracil mustard
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
Uracil mustard + Mechlorethamine
|
DCMGPF4
|
Uracil mustard
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
Uracil mustard + Mechlorethamine
|
DCZWWHF
|
Uracil mustard
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Vandetanib + Mechlorethamine
|
DCT445E
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[5] |
Vandetanib + Mechlorethamine
|
DCO73AM
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
Vandetanib + Mechlorethamine
|
DC7OVNJ
|
Vandetanib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Vandetanib + Mechlorethamine
|
DCEX87T
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[5] |
Vemurafenib + Mechlorethamine
|
DCVDNVK
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
Vemurafenib + Mechlorethamine
|
DCFTERU
|
Vemurafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[5] |
Vemurafenib + Mechlorethamine
|
DCEJWH5
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[5] |
Vemurafenib + Mechlorethamine
|
DCVYL0Y
|
Vemurafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
Vemurafenib + Mechlorethamine
|
DC6992A
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
Vemurafenib + Mechlorethamine
|
DCEPRNE
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[5] |
Vemurafenib + Mechlorethamine
|
DCATCNW
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[5] |
Vismodegib + Mechlorethamine
|
DCZB6M0
|
Vismodegib
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
Vismodegib + Mechlorethamine
|
DCS2BV2
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[5] |
Vismodegib + Mechlorethamine
|
DCP6JLN
|
Vismodegib
|
Astrocytoma (Cell Line: SNB-19)
|
[5] |
Vismodegib + Mechlorethamine
|
DCG69HU
|
Vismodegib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[5] |
------------------------------------------------------------------------------------ |
|
|
|
|